Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $1,386,750.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $92.45, for a total value of $1,386,750.00. Following the sale, the chief executive officer now directly owns 450,301 shares of the company’s stock, valued at approximately $41,630,327.45. This trade represents a 3.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Grant Pickering also recently made the following trade(s):

• On Thursday, November 7th, Grant Pickering sold 2,366 shares of Vaxcyte stock. The stock was sold at an average price of $103.89, for a total value of $245,803.74.
• On Friday, November 1st, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $106.82, for a total value of $1,602,300.00.
• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The shares were sold at an average price of $109.21, for a total transaction of $775,172.58.

Vaxcyte Trading Down 1.3 %

Vaxcyte stock traded down $1.23 during trading hours on Tuesday, reaching $90.37. 869,477 shares of the stock were exchanged, compared to its average volume of 906,759. Vaxcyte, Inc. has a twelve month low of $52.74 and a twelve month high of $121.06. The stock has a 50 day moving average of $104.69 and a two-hundred day moving average of $90.71. The company has a market cap of $11.26 billion, a P/E ratio of -19.65 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the business posted ($0.91) earnings per share. On average, analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Jefferies Financial Group raised their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $147.50.

Institutional Trading of Vaxcyte

Institutional investors have recently made changes to their positions in the company. Tidal Investments LLC bought a new position in shares of Vaxcyte in the first quarter worth $405,000. Teachers Retirement System of The State of Kentucky lifted its stake in Vaxcyte by 16.6% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 25,059 shares of the company’s stock worth $1,712,000 after purchasing an additional 3,564 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Vaxcyte by 392.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock valued at $3,046,000 after purchasing an additional 32,149 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Vaxcyte during the 2nd quarter valued at $202,000. Finally, J.Safra Asset Management Corp raised its position in shares of Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after buying an additional 526 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.